The Drug Company That Does Not Own a Single Plant
Pharmaceutical companies increasingly do not own the plants that make their products. Contract manufacturers supply capacity across many customers, which turns a capital intensive fixed cost into a purchased service.
The Bet a Plant Represents
Pharmaceutical manufacturing requires facilities built to demanding standards, validated with regulators, and dedicated to specific processes. Construction and qualification take years and cost hundreds of millions for a commercial scale biologics facility.
The decision to build must be made before a drug is approved, because capacity cannot be created after approval without delaying launch. So a company either commits capital to a plant for a product that may fail, or risks having no capacity if it succeeds.
A contract development and manufacturing organisation offers a third option: buy capacity from somebody who has already built it and serves many customers.
Why the Economics Work
| For the Sponsor | For the Manufacturer |
|---|---|
| No capital commitment before approval | Capacity utilised across many customers |
| Access to specialised process capability | Accumulated process expertise |
| Faster scale up | Long term contracts and reservation fees |
| Loses control of a critical input | Exposed to customer product failures |
The utilisation argument is the core of it. A dedicated plant serving one product runs at whatever that product requires. A contract facility can fill the gaps between customers, which spreads a very large fixed cost across more output.
The sponsor has converted an irreversible capital decision made under uncertainty into a purchased service. What it has given up is control of a step that regulators hold it responsible for and that it cannot quickly replace.
The Switching Problem
The dependency is more severe than in ordinary outsourcing, because manufacturing processes are registered with regulators.
Moving production to a different facility requires technology transfer, comparability studies demonstrating the product is unchanged, and regulatory approval of the new site. For a biologic, where the product is defined partly by the process that makes it, this can take years.
The practical consequence is that a sponsor cannot respond to a price increase or a service failure by switching supplier on any commercially useful timescale. That asymmetry shapes contract negotiations and is why sponsors of important products increasingly qualify a second source despite the cost of doing so.
The Modality Divide
The industry splits along product type and the economics differ substantially.
Small molecule manufacturing is chemical synthesis. Capacity is relatively fungible across products, competition is broad, and margins are correspondingly thinner.
Biologics are produced in living cells, require far more specialised facilities, and involve process knowledge that is genuinely difficult to replicate. Capacity has been tight for extended periods, which has supported pricing and long term reservation arrangements.
Cell and gene therapies are more specialised still, frequently manufactured per patient, with limited qualified capacity globally and correspondingly strong supplier position.
A company describing itself as a contract manufacturer could be operating in any of these with entirely different competitive dynamics, which is why the modality mix matters more than the revenue figure.
The Reservation Structure
Because capacity must be built before demand is certain, contracts increasingly include take or pay commitments: the customer reserves capacity and pays for it whether or not it is used.
That is the same structure used to finance any dedicated long lived asset, and it appears here for the same reason. A manufacturer will not build a suite for a customer without a commitment, and the customer accepts the commitment because the alternative is having no capacity.
The consequence appeared visibly when demand for certain products fell short of forecast and customers had reserved capacity they no longer needed. Those obligations flowed through as charges, and the manufacturers recognised revenue for output nobody took.
The Concentration Risk
Outsourcing manufacturing has produced supply chain concentration that policymakers noticed only when it was tested.
A substantial share of active pharmaceutical ingredient production for generic medicines is concentrated in a small number of countries and, for some molecules, in a small number of plants. A regulatory action or an outage at one facility can produce a national shortage of a widely used medicine.
Government responses have included funding domestic capacity, stockpiling, and requirements for supply chain disclosure. The underlying economics remain unchanged, since generic manufacturing is a low margin business where cost determines location.
How to Read the Sector
Useful measures include capacity utilisation, which drives margin directly; customer concentration, since a manufacturer heavily dependent on one product is exposed to that product commercial performance; the modality mix; and the balance between development stage and commercial stage work, since development revenue is smaller but leads to commercial contracts and is therefore a forward indicator.
The sector is also cyclical in a way that surprises people, because it depends on biotechnology funding. When capital markets close to small biotechnology companies, development programmes are cancelled and the manufacturers lose the work that would have become commercial supply years later.
The Bottom Line
Contract manufacturing lets a pharmaceutical company avoid committing capital to a plant for a product that may never be approved, and it transfers a critical dependency to a supplier that cannot be replaced quickly because regulators registered the process. Capacity reservation contracts finance the buildings and leave customers paying for output they may not need. The concentration that resulted is efficient and produces shortages when a single facility fails, which is a tradeoff nobody chose deliberately and everybody now owns.